Dasotraline in Children with Attention-Deficit/Hyperactivity Disorder: A Six-Week, Placebo-Controlled, Fixed-Dose Trial | Zendy

Robert L. Findling | Zendy; Lenard A. Adler | Zendy; Thomas Spencer | Zendy; Robert Goldman | Zendy; Seth C. Hopkins | Zendy; Kenneth S. Koblan | Zendy; Justine Kent | Zendy; Jay Hsu | Zendy; Antony Loebel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Dasotraline in Children with Attention-Deficit/Hyperactivity Disorder: A Six-Week, Placebo-Controlled, Fixed-Dose Trial

Author(s) -

Robert L. Findling,

Lenard A. Adler,

Thomas Spencer,

Robert Goldman,

Seth C. Hopkins,

Kenneth S. Koblan,

Justine Kent,

Jay Hsu,

Antony Loebel

Publication year - 2019

Publication title -

journal of child and adolescent psychopharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.935

H-Index - 84

eISSN - 1557-8992

pISSN - 1044-5463

DOI - 10.1089/cap.2018.0083

Subject(s) - placebo , discontinuation , attention deficit hyperactivity disorder , rating scale , clinical global impression , randomized controlled trial , adverse effect , medicine , clinical endpoint , atomoxetine hydrochloride , psychology , pediatrics , psychiatry , methylphenidate , atomoxetine , developmental psychology , alternative medicine , pathology

Dasotraline is a potent inhibitor of presynaptic dopamine and norepinephrine reuptake with a pharmacokinetic profile characterized by slow absorption and a long elimination half-life. The aim of this study was to evaluate the efficacy and safety of dasotraline in children with attention-deficit/hyperactivity disorder (ADHD).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research